---
title: Improved Care and Treatment Options for Patients with Hyperphagia-Associated
  Obesity in Bardet-Biedl Syndrome
date: '2024-03-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38458231/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240309170632&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive multisystem
  disease. The pathophysiological origin is a dysfunction of the primary cilium. Clinical
  symptoms are heterogeneous and variable: retinal dystrophy, obesity, polydactyly,
  kidney abnormalities, hypogenitalism and developmental delays are the most common
  features. By the approval of the melanocortin 4 receptor agonist setmelanotide,
  a drug therapy for BBS-associated hyperphagia and obesity can be offered for the
  first ...'
disable_comments: true
---
Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive multisystem disease. The pathophysiological origin is a dysfunction of the primary cilium. Clinical symptoms are heterogeneous and variable: retinal dystrophy, obesity, polydactyly, kidney abnormalities, hypogenitalism and developmental delays are the most common features. By the approval of the melanocortin 4 receptor agonist setmelanotide, a drug therapy for BBS-associated hyperphagia and obesity can be offered for the first ...